Extradurale Lipomatose nach langjähriger Steroidbehandlung

N. Burkhardt,G. Hamann

DOI: https://doi.org/10.1007/s00115-006-2180-1

2006-12-01

Der Nervenarzt

Abstract:

What problem does this paper attempt to address?

Comparison of the Efficacy and Safety of Bilastine 20 mg versus Fexofenadine 180 mg for Treatment of Perennial Allergic Rhinitis: Randomized Controlled Study

Aditya Singhal,Pooja Agrawal,Probal Chatterji,Pritpal Singh Matreja,Tariq Mahmood

DOI: https://doi.org/10.1007/s12070-024-04770-0

Abstract:Background: Antihistamines has always remained the mainstay drug treatment for Allergic Rhinitis (AR). Bilastine is a novel, non-sedative antihistamine with a super-selective H1 receptor antagonist property. Both bilastine and fexofenadine are second generation antihistamine drugs commonly used to manage AR and Chronic Urticaria (CU). Autologous Skin Serum Test (ASST) is a practical test for histamine release in CU. These tests have been studied in AR patients with limited data studies. Methods: 114 patients diagnosed with perennial AR were recruited and divided into two groups of 57 each. One group was started Bilastine 20 mg once a day and other group, fexofenadine 180 mg once a day. Total Nasal Symptom Score (TNSS) was calculated at presentation and two weeks of antihistamine therapy. ASST was hypothesized to be the test for AR and performed at the time of presentation and at two weeks follow-up. Intergroup and Intragroup assessment of TNSS, ASST and its variables were done using unpaired and paired t test respectively. Results: Patients showed reduction in symptoms of AR with both antihistamines. A significant improvement of sneezing and rhinorrhoea was seen in Fexofenadine group as compared to Bilastine group. TNSS showed statistically significant improvement in both the groups. ASST had statistically significant reduction in both the groups. Conclusions: Both Bilastine and fexofenadine were found to be effective in reduction of symptoms of allergic rhinitis. Bilastine was found to be more effective in overall as well as sneezing and rhinorrhoea noted two weeks after therapy. Supplementary information: The online version contains supplementary material available at 10.1007/s12070-024-04770-0.
A Corporate Credit Rating Model Using Support Vector Domain Combined with Fuzzy Clustering Algorithm

Xuesong Guo,Zhengwei Zhu,Jia-lian Shi

DOI: https://doi.org/10.1155/2012/302624

2012-07-25

Abstract:Corporate credit-rating prediction using statistical and artificial intelligence techniques has received considerable attentions in the literature. Different from the thoughts of various techniques for adopting support vector machines as binary classifiers originally, a new method, based on support vector domain combined with fuzzy clustering algorithm for multiclassification, is proposed in the paper to accomplish corporate credit rating. By data preprocessing using fuzzy clustering algorithm, only the boundary data points are selected as training samples to accomplish support vector domain specification to reduce computational cost and also achieve better performance. To validate the proposed methodology, real-world cases are used for experiments, with results compared with conventional multiclassification support vector machine approaches and other artificial intelligence techniques. The results show that the proposed model improves the performance of corporate credit-rating with less computational consumption.
[Effects of temperature and pH on digestive enzymes activities in Whitmania pigra].

Hongzhuan Shi,Q. Guo,Zaibiao Zhu,T. Hu,Shuai-wen Zhang

DOI: https://doi.org/10.4268/cjcmm20121707

2012-09-01

Abstract:OBJECTIVE Current study was conducted to investigate and compare the impact of temperature and pH on the activities of amylase, protease and lipase in alimentary tract of Whitmania pigra. METHOD The responses of amylase, protease, and lipase activities were determined over a wide range of temperatures (7-52 degrees C) and pH gradient (2.2-11.2). RESULT The highest lipase activity was found under 37 degrees C, pH 8.2, and the highest amylase activity was detected under 37 degrees C, pH 5.2, while protease activity peaked at 42 degrees C, pH 3.2 or pH 9.2. CONCLUSION The optimal temperature in alimentary tract of Wh. pigra for lipase and amylase was 37 degrees C, and the responding temperature for protease was 42 degrees C. The optimal pH value in alimentary tract of Wh. pigra for lipase and amylase was pH 8.2 and pH 5.2, respectively. While pH 3.2 or 9.2 seems to be both favorable for high protease activity.
TITLE ( PROVISIONAL ) The effect of early goal-directed therapy on mortality in patients with severe sepsis or septic shock : a meta-analysis of randomized controlled trials

Hong Yu,B. Liu

Abstract:Methodology Concerns These trials were conducted 8 years after the EGDT trial lasting 4 to 8 years in duration. a. The SSC guidelines were published in 2004, 2008, and 2012 during the trial conduction. b. Lactate screening and antibiotics were standard care prior to enrollment and required, not in the EGDT study. c. Sudden cardiopulmonary events were eliminated as a cause of mortality and not acknowledged after the EGDT study. d. Pre-hospital care, sepsis alerts, rapid response systems, telemedicine, and palliative care have evolved since EGDT and have changed mortality. e. 4-6 hour rules to decrease ED overcrowding in ARISE and ProMISE trials and ICU admission in less in less than hours. The EGDT patients stayed in the ED for a minimum of 6-8 hours.
Oxygen delivery and uptake by peripheral tissues: physiology and pathophysiology.

P. Schumacker,R. W. Samsel

DOI: https://doi.org/10.1016/S0749-0704(18)30435-4

IF: 3.879

1989-04-01

Critical Care Clinics

Abstract:
The role of ACTH, cortisone and hydrocortisone in surgery.

W. Abbott,H. Krieger,S. Levey

DOI: https://doi.org/10.7326/0003-4819-43-4-702

IF: 39.2

1955-10-01

Annals of Internal Medicine

Abstract:Excerpt During the past few years a considerable amount of knowledge concerning the use and abuse of ACTH, cortisone and hydrocortisone in the treatment of surgical patients has accumulated. Metabo...
A Real-World Observational Study to Evaluate the Safety and Effectiveness of Fluticasone Furoate–Oxymetazoline Fixed Dose Combination Nasal Spray in Patients with Allergic Rhinitis

Meenesh R. Juvekar,Gauri Kapre Vaidya,Aniruddha Majumder,Amod D. Pendharkar,Anthony Irudhayarajan,Avijit Kundu,D. Ramesh,J. Dheeraj Kumar,B. Jagannatha,Joseph Mathew,Mahesh P. Nikam,Madhuri Mehta,Neeraj Chawla,Priti Hajare,P. G. Chandre Gowda,P. V. L. N. Murthy,Suma Moni Mathew,Makarand V. Damle,Chandra Kant,Arun B. Nair,Ashok Jaiswal,Ravi T. Mehta

DOI: https://doi.org/10.1007/s40261-023-01338-8

2024-01-11

Clinical Drug Investigation

Abstract:Allergic rhinitis (AR) has shown an increasing prevalence leading to a considerable medical and social burden. Nasal congestion is the cardinal symptom of AR, and the upper respiratory tract is most affected by this long-lasting ailment. Intranasal corticosteroids alleviate nasal congestion, along with other symptoms of AR, but their effect is not evident immediately. Oxymetazoline has a rapid onset of action, but its use should be limited to 3–5 days.

pharmacology & pharmacy
A Comparative, Three-Arm, Randomized Clinical Trial to Evaluate the Effectiveness and Tolerability of Bilastine vs Fexofenadine vs Levocetirizine at the Standard Dose and Bilastine vs Fexofenadine at Higher Than the Standard Dose (Up-Dosing) vs Levocetirizine and Hydroxyzine (in Combination) in Patients with Chronic Spontaneous Urticaria

Bela Shah,Dhiraj Dhoot,Ankita Choudhary,Neha Jangid,Deval Mistry,Shikha Shah,Shruti Kamat,Hanmant Barkate

DOI: https://doi.org/10.2147/CCID.S350122

2022-02-18

Abstract:Introduction: Though second-generation antihistamines (SGAH) are first-line drugs in chronic spontaneous urticaria (CSU), 50% of patients do not respond to them. In such patients, guidelines recommend either up-dosing of SGAH or combination of different antihistamines. However, the studies comparing these treatment regimens are limited. Methods: In this comparative, three-arm study, CSU patients were randomized to receive standard dose of either bilastine, fexofenadine, or levocetirizine for 2 weeks. After 2 weeks of treatment, non-responders received double dose of either bilastine or fexofenadine, while hydroxyzine 25 mg once daily was added in the levocetirizine group. Patients were primarily evaluated for improvement in CSU, quality of life, and somnolence. Results: A total of 110 patients with CSU were recruited. At the end of 4 weeks, 33/39, 26/35, and 22/36 patients in the bilastine, fexofenadine, and levocetirizine groups showed improvement in urticaria symptoms. At week 2, there was no statistical difference in urticaria activity score (UAS7) improvement between any of the groups; however, at week 4, there was a statistical difference between the bilastine and levocetirizine groups (p<0.05). Somnolence was significantly lower in the bilastine group (p<0.05). Bilastine was statistically significant (p<0.05) in the improvement of quality of life as compared to both groups. No major adverse events were reported during study period; however, bilastine was associated with significantly lower levels of AEs compared to levocetirizine (p<0.05). Conclusion: Two-fold up-dosing of bilastine improves CSU symptoms without compromising safety as compared to two-fold up-dosing of fexofenadine and combination of first- and second-generation antihistamines.
Pharmacokinetics and Safety of Bilastine 10 mg/d in Children Aged 2 to 5 Years With Allergic Rhinoconjunctivitis or Urticaria: A Phase 3 Clinical Trial

B Majorek-Olechowska,T Slomskis,L Zollerová,I Martín,C Sánchez,I Gilaberte,P Arranz,BILA-4021/PED Research Group

DOI: https://doi.org/10.18176/jiaci.1003

2024-05-10

Abstract:Background: Bilastine is a second-generation antihistamine for the symptomatic treatment of allergic rhinoconjunctivitis (ARC) and urticaria in adults, adolescents, and children. The pharmacokinetics and safety of oral bilastine 10 mg/d in children aged 2 to 5 years were evaluated. Methods: This was a multicenter, open-label clinical trial in children aged 2 to 5 years with seasonal or perennial ARC or urticaria treated once daily with bilastine 10 mg orodispersible tablets. The safety evaluation included treatment-emergent adverse events (TEAEs), vital signs, and physical examination. Pharmacokinetic data were pooled with data from a prior pediatric study, and pharmacokinetic modeling was performed to assess consistency. Results: A total of 37 children with ARC (81.1%), urticaria (8.1%), or both (10.8%) were included in the study, with a mean (SD) age of 3.7 (1.2) years. The highest plasma concentrations of bilastine were observed 1 hour after administration (634.91 ng/mL). Eight patients (21.6%) experienced 1 TEAE each, none of which was severe. Body weight and age were not covariates of variation in either systemic clearance or the volume of distribution in children aged 2 to 5 years and did not affect the pharmacokinetic parameters of bilastine. Conclusions: The pharmacokinetics of bilastine was linear and consistent with data from a previous trial, suggesting that a 10-mg dose may be used in children (2 to <12 years). No dose adjustments are deemed necessary. Oral once-daily bilastine 10 mg presented a good safety profile in children aged 2 to 5.
Comparative study of efficacy and safety of cetirizine and bilastine in patients of chronic spontaneous urticaria: Open-label, randomized, parallel-group study

Vishakha V Sinha,Mrunalini Vinay Kalikar,Jayesh Ishwardas Mukhi,Akhil Bhagwan Giradkar,Smita Sontakke

DOI: https://doi.org/10.4103/picr.picr_28_23

Abstract:Purpose: Bilastine is a novel second-generation antihistaminic. Very few studies in Indian population have compared the safety and efficacy of bilastine with other second-generation antihistaminic like cetirizine. Hence, the present study was planned. Materials and methods: This was a randomized, open-label comparative parallel group study conducted on 70 patients of chronic spontaneous urticaria (CSU). Patients either received cetirizine 10 mg or bilastine 20 mg once daily for 6 weeks. The primary endpoint was to find out the difference in the mean total symptom score (MTSS) at baseline and 6 weeks. The secondary endpoint was to find out changes in the scale of the number of wheals, change in pruritus scale, scale for size of wheal, change for interference of wheals with sleep, change in visual analog scale (VAS) for sedation, change in scale for intensity of erythema, and change in Scale for Extent of Skin Area Involvement (SESI). Results: Bilastine and cetirizine offer a significant reduction in MTSS, mean number of wheals, and mean pruritus scale at baseline to 1, 3, and 6 weeks. The mean difference in MTSS was significantly more in bilastine. Cetirizine showed a significant increase in VAS score for sedation as compared to bilastine. Both the drugs were well tolerated and safe. Adverse events like headache, gastric irritation, dryness of mouth, and sedation were more reported in cetirizine group. Conclusion: Bilastine was more efficacious than cetirizine in patients of CSU and the efficacy was seen earlier at 1 week, which was not seen in the cetirizine group.
Gene therapy for the prevention of corneal haze after photorefractive/phototherapeutic keratectomy excimer laser surgery.

A. Behrens,P. McDonnell

DOI: https://doi.org/10.1007/978-1-4615-0717-8_191

Advances in experimental medicine and biology

Abstract:
Comparative Efficacy of Mometasone Nasal Spray Combined with Different Doses of Desloratadine, and Montelukast in Childhood Allergic Rhinitis: A Randomized Clinical Trial

Niloufar Ghanbari,Kambiz Eftekhari,Mohammadreza Samadzadeh-Mamaghani,Mohsen Sedighiyan,Diana Noemi Diaz,Alireza Shafiei

DOI: https://doi.org/10.18502/ijaai.v23i4.16211

2024-08-19

Iranian Journal of Allergy Asthma and Immunology

Abstract:Allergic rhinitis is a common childhood disease. Although various drugs have been used to treat allergic rhinitis, including nasal corticosteroids, antileukotrienes, and antihistamines, there is still controversy about the optimal dose and the best combination with the highest efficacy. Higher doses of antihistamines are recommended for better control of urticaria, but there is insufficient evidence regarding the efficacy of increased doses of antihistamines in allergic rhinitis. The aim of the study was to evaluate the effectiveness of different drug combinations in the treatment of children with allergic rhinitis. Sixty-four children with persistent moderate to severe allergic rhinitis were enrolled and randomly divided into 4 groups. All children received mometasone furoate nasal spray once daily. In addition to mometasone, each group received one of the following drugs or drug combinations: daily desloratadine, twice daily desloratadine, montelukast, or a combination of desloratadine and montelukast. The severity of symptoms before and after the intervention was evaluated based on the total nasal symptoms score, including sneezing, nasal congestion, nasal itching, and rhinorrhea. Sixty patients completed the study. The reduction of nasal congestion score and total nasal symptoms score in the groups receiving desloratadine twice a day and desloratadine plus montelukast was superior to the daily desloratadine group and daily montelukast groups. According to this work, the treatment of allergic rhinitis with mometasone nasal spray with desloratadine twice a day or with the combination of desloratadine and montelukast was more effective than other treatment regimens.

immunology,allergy
Comparison of the pharmacokinetics and tolerability of montelukast/levocetirizine administered as a fixed-dose combination and as separate tablets

Seokuee Kim,Jae-Wook Ko,Jung-Ryul Kim

DOI: https://doi.org/10.5414/CP203265

Abstract:Objective: A novel fixed-dose combination (FDC) capsule of 10/5 mg of montelukast/levocetirizine may lead to better compliance than two separate tablets taken together. The aim of this study was to evaluate the pharmacokinetics (PK) and tolerability of an FDC of montelukast and levocetirizine compared to separate tablets. Materials and methods: A randomized, open-label, single-dose, two-sequence, two-period, crossover study was conducted with healthy male subjects. In each period, either an FDC or separate tablets were administered orally, and serial blood samples were collected for PK analysis for up to 34 hours after dosing. PK parameters were calculated using noncompartmental methods. The 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) of the maximum plasma concentration (Cmax) and the area under the curve to the last measurable concentration (AUClast) for the two interventions were estimated. Tolerability assessments were performed for all the subjects who received the drug at least once. Results: The PK profiles of the two interventions were comparable. For montelukast, the GMRs and 90% CIs for the Cmax and AUClast were 0.9800 (0.8903 - 1.0787) and 1.0706 (0.9968 - 1.1498), respectively. The corresponding values for levocetirizine were 0.9195 (0.8660 - 0.9763) and 1.0375 (1.0123 - 1.0634), respectively. Both interventions were well tolerated. Conclusion: The PK and tolerability profiles of montelukast and levocetirizine after a single oral administration were comparable between the FDC and separate tablets. For patients with allergic rhinitis who require a combination treatment, the FDC of montelukast and levocetirizine will be a convenient therapeutic option. .
Double-blind, placebo-controlled trial of the efficacy and safety of azelastine hydrochloride in children with perennial allergic rhinitis

Jean Bousquet,Ludger Klimek,Hans-Christian Kuhl,Duc Tung Nguyen,Rajesh Kumar Ramalingam,G Walter Canonica,William Berger

DOI: https://doi.org/10.1159/000542054

2024-12-06

Abstract:Background: Allergic rhinitis (AR) affects up to 40% of the pediatric population. The US practice parameter recommends the use of INAH or INCS as first-line therapy for the treatment of AR. Although not directly targeted to children, the recent US Practice Parameters proposed intranasal antihistamines as first-line therapy whereas the ARIA guidelines did not. Methods: This was a randomized, double-blind, parallel-group study with a duration of 28 days. It compared Azelastine hydrochloride 0.10% and 0.15% to placebo of one spray per nostril twice daily in pediatric subjects with moderate-to-severe symptomatic perennial allergic rhinitis (PAR). Results: A total of 486 subjects were included in the study. The change from baseline rTNSS was statistically significant for 0.15% AZE (P = .005) and 0.10% AZE (P = .015) vs. placebo. 0.15% AZE showed an LS mean change of -3.45 (20.2%) over the 28-day treatment period from a baseline value of 16.60 in rTNSS. 0.10% AZE showed an LS mean change of -3.37 (20.5%) over the 28-day treatment period from a baseline value of 16.35 in rTNSS. Somnolence was reported by one patient in the 0.1% group and one placebo patient (both of mild severity and unlikely to be related to treatment). None of the patients reported fatigue. Conclusions: 0.15% AZE significantly improved the overall rTNSS compared with placebo over the 28-day study period. 0.15% AZE was well tolerated in this study.
Opportunities for correction of individual links of the pathogenesis of allergic rhinitis and bronchial asthma with assessment of the quality of life of patients

M. Yu. Korkmazov,M. A. Lengina,I. D. Dubinets,A. M. Korkmazov,A. A. Smirnov

DOI: https://doi.org/10.21518/2079-701x-2022-16-4-24-34

2022-04-05

Meditsinskiy sovet = Medical Council

Abstract:Introduction . One of the antileukotriene drugs for the treatment of bronchial asthma and allergic rhinitis with and without polyposis is montelukast. The presented article presents the results of the analysis of the effectiveness, safety and impact on the quality of life of patients, the use of the singular, in various forms of allergic rhinitis and associated comorbid conditions. Aim of the study . To assess the impact on the quality of life of patients, the effectiveness and safety of the use of montelukast in the complex therapy of patients with allergic rhinitis and comorbid diseases. Materials and methods. A simple, blind, randomized, controlled clinical trial involved 97 patients divided into 4 groups: patients with moderate allergic rhinitis; allergic rhinitis of moderate severity and bronchial asthma; severe allergic rhinitis and bronchial asthma; severe allergic rhinitis, bronchial asthma and polypous rhinosinusitis. In parallel with the comparison of drug tolerability, safety and clinical symptoms (rhinorrhea, nasal congestion, itching, sneezing, bronchopulmonary manifestations), the quality of life was assessed using a special SNOT-22 questionnaire. Results . The use of the antileukotriene drug montelukast in the complex therapy of allergic rhinitis and related comorbid conditions significantly improved the clinical symptoms and quality of life of patients over the entire period of treatment in all groups. There was an increase in the suppression of leukotriene-mediated effects when using montelukast, more in the group of people with allergic rhinitis and bronchial asthma, such as symptoms of the allergic triad, mucus hypersecretion, bronchospasm, eosinophilia, increased vascular permeability, etc. Conclusion . In the treatment of patients with allergic rhinitis and morbid conditions, Singular has demonstrated an inhibitory effect on cysteinyl leukotrienes, high bioavailability, good tolerability and safety.

English Else
[Ajmalin in the treatment of cardiac arrhythmias in children].

T. Lewenfisz-Wojnarowska,A. Chrościcki,J. Grzybowska,D. Jarzebska,K. Kubicka

1968-03-01

Pediatria Polska

Abstract:
RHEUMATIC PNEUMONITIS Figure 3

R. Massumi,J. Legier

Abstract:IN THE COURSE of acute rheumatic fever the occurrence of pulmonary infiltrates is often considered a manifestation of pulmonary congestion, unrelated viral or bacterial pneumonitis, atelectasis, or infarction. These interpretations are undoubtedly correct frequently but cannot apply to all cases. Inasmuch as the pathologic process in acute rheumatic fever is known to be a diffuse one and capable of involving the vascular system and connective tissue in a wide variety of organ systems,1-4 the question of rheumatic pneumonitis may be logically advanced in such cases. The following presentation of two fatal cases with postmortem documentation and
Goblet cell carcinoid of appendix. Ultrastructural features and histogenetic aspects

T. Warner,I. Seo

DOI: https://doi.org/10.1002/1097-0142(197911)44:5<1700::AID-CNCR2820440525>3.0.CO;2-T

IF: 6.9209

1979-11-01

Cancer

Abstract:Light and electron microscopic examination of a goblet cell carcinoid revealed cells with pleomorphic neurosecretory‐type granules, cells containing mucin some of which also contained these granules and less differentiated cells lacking the aforementioned features. Recent embryologic and anatomic studies of developing avian and mammalian gut, respectively, show that intestinal APUD cells are probably of endodermal origin. Therefore, mixed carcinoid tumors such as the goblet cell variant could arise in crypt base stem cells.
Comparative efficacy of combined antihistamine and montelukast therapy in adult patients with atopic dermatitis

Kristina R. Jamalyan,Helen G. Azaryan

DOI: https://doi.org/10.5114/ada.2023.135759

2024-01-01

Advances in Dermatology and Allergology

Abstract:Introduction: Atopic dermatitis (AD) is one of the most common chronic skin conditions affecting about 20% of children and 5% of adults. However, the studies assessing novel therapies for AD have been focused mainly on paediatric patients and only few studies have involved adult participants.Aim: To compare the treatment outcomes between the antihistamine monotherapy and combined intervention with an antihistamine agent and a cysteinyl leukotriene receptor antagonist in adult patients with atopic dermatitis.Material and methods: Patients were randomized into two groups to receive 5 mg oral desloratadine or the combined therapy with 5 mg oral desloratadine and 10 mg montelukast. Both groups were also administered topical treatment using the same protocol (topical Elocon and moisturizer). To estimate the efficacy of the implemented therapy methods, different skin health scores (SCORAD, GISS, EASI, PPNRS and DLQI) and skin functional assessment outcomes (corneometry, pH and transepidermal water loss) were evaluated before and after the treatment.Results: Significant differences were revealed in compared measurement results for scales of the Extent and Severity of Eczema assessment, Global Individual Signs Score, Eczema Area and Severity Index, Pruritus Numerical Rating Scale, Dermatology Life Quality Index and Skin Functional Properties (p > 0.05).Conclusions: Comparison of data presenting the therapy outcomes in two groups showed that administration of the combined therapy was significantly more effective compared to the antihistamine monotherapy. The results revealed considerable efficacy of the combined therapy reinforced by the use of cysteinyl leukotriene receptor antagonist, montelukast.

dermatology,allergy
Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Chenjie Yu,Kaijian Wang,Xinyan Cui,Ling Lu,Jianfei Dong,Maohua Wang,Xia Gao

DOI: https://doi.org/10.1177/1945892419884774

2019-11-01

American Journal of Rhinology and Allergy

Abstract:Background Patients with moderate to severe allergic rhinitis (AR) who are treated according to the current rhinitis management guidelines may be inadequately controlled. These patients are at risk of serious comorbidities, such as asthma and chronic sinusitis. These symptoms, sneezing and an itchy, runny, stuffy nose, may have a negative impact on patients’ daily functioning. Omalizumab is being developed as a new choice for the treatment of AR. We therefore undertook a meta-analysis to assess the efficacy and safety of omalizumab in the treatment of AR. Methods We systematically searched PubMed, Cochrane Library, and MEDLINE databases for randomized controlled studies on the treatment of AR with omalizumab. Our evaluation outcomes were symptom scores, medication efficacy, combined symptom and medication scores, and adverse events. We descriptively summarized and quantitatively synthesized original data to evaluate the efficacy and safety of omalizumab in the treatment of AR by using Stata12.0 software for meta-analyses. Results The results of our meta-analysis showed that there were statistically significant differences between the omalizumab group and the control group in the following aspects: daily nasal symptom score (standardized mean difference [SMD] = –0.443, 95% confidence interval [CI]: –0.538 to –0.347, P < .001); daily ocular symptom score (SMD = –0.385, 95% CI: –0.5 to –0.269, P < .001); daily nasal medication symptom scores (SMD = –0.421, 95% CI: –0.591 to –0.251, P < .001); proportion of days of emergency drug use (risk ratio [RR] = 0.488, 95% CI: 0.307 to 0.788, P < .005); rhinoconjunctivitis-specific quality of life questionnaire (SMD = –0.286, 95% CI: –0.418 to –0.154, P < .001); and overall evaluation (RR = 1.435, 95% CI: 1.303–1.582, P < .001). There was no statistically significant difference in safety indicator: adverse events (RR = 1.026, 95% CI: 0.916–1.150, P = .655). Conclusion Omalizumab is effective and relatively safe in patients with AR; omalizumab used in conjunction with special immunotherapy has shown promising results, especially in reducing adverse events.

Extradurale Lipomatose nach langjähriger Steroidbehandlung

Comparison of the Efficacy and Safety of Bilastine 20 mg versus Fexofenadine 180 mg for Treatment of Perennial Allergic Rhinitis: Randomized Controlled Study

A Corporate Credit Rating Model Using Support Vector Domain Combined with Fuzzy Clustering Algorithm

[Effects of temperature and pH on digestive enzymes activities in Whitmania pigra].

TITLE ( PROVISIONAL ) The effect of early goal-directed therapy on mortality in patients with severe sepsis or septic shock : a meta-analysis of randomized controlled trials

Oxygen delivery and uptake by peripheral tissues: physiology and pathophysiology.

The role of ACTH, cortisone and hydrocortisone in surgery.

A Real-World Observational Study to Evaluate the Safety and Effectiveness of Fluticasone Furoate–Oxymetazoline Fixed Dose Combination Nasal Spray in Patients with Allergic Rhinitis

Pharmacokinetics and Safety of Bilastine 10 mg/d in Children Aged 2 to 5 Years With Allergic Rhinoconjunctivitis or Urticaria: A Phase 3 Clinical Trial

Comparative study of efficacy and safety of cetirizine and bilastine in patients of chronic spontaneous urticaria: Open-label, randomized, parallel-group study

Gene therapy for the prevention of corneal haze after photorefractive/phototherapeutic keratectomy excimer laser surgery.

Comparative Efficacy of Mometasone Nasal Spray Combined with Different Doses of Desloratadine, and Montelukast in Childhood Allergic Rhinitis: A Randomized Clinical Trial

Comparison of the pharmacokinetics and tolerability of montelukast/levocetirizine administered as a fixed-dose combination and as separate tablets

Double-blind, placebo-controlled trial of the efficacy and safety of azelastine hydrochloride in children with perennial allergic rhinitis

Opportunities for correction of individual links of the pathogenesis of allergic rhinitis and bronchial asthma with assessment of the quality of life of patients

[Ajmalin in the treatment of cardiac arrhythmias in children].

RHEUMATIC PNEUMONITIS Figure 3

Goblet cell carcinoid of appendix. Ultrastructural features and histogenetic aspects

Comparative efficacy of combined antihistamine and montelukast therapy in adult patients with atopic dermatitis

Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials